LONDON, March 12, 2026, 19:35 GMT
- Smith & Nephew ended the day at 1,240.5 pence, slipping 0.24%. The FTSE 100 dropped 0.4%.
- On March 10, the company rolled out ALLEVYN COMPLETE CARE in the U.S.—a five-layer foam dressing aimed at wounds and pressure sores—with broader international expansion planned for 2026.
- Investors haven’t stopped parsing that projected $60 million tariff impact for 2026, and there’s lingering uncertainty over management’s ability to stick to guidance this year.
Smith & Nephew slipped 0.24% to finish at 1,240.5 pence on Thursday, as shares drifted lower just days after the FTSE 100 medical-device group launched a fresh wound-care line. The broader London market struggled as well, with the blue-chip index dropping 0.4%—renewed inflation jitters flaring up on the back of rising oil prices.
The March 10 debut of ALLEVYN COMPLETE CARE marks one of the first concrete signs of Smith & Nephew’s 2026 product cycle—and it comes right after management closed out a three-year turnaround and reiterated its forecast. Investors, however, aren’t letting go of the risk factors flagged in the annual report: tariffs, supply chain turmoil linked to conflicts, and the possibility that guidance could wobble before the year is out.
Smith & Nephew’s new five-layer foam dressing is aimed at managing wounds and reducing the risk of pressure sores. The company is rolling it out in the U.S. first, with launches in Europe and other regions pushed to later in 2026. “A true next-generation dressing,” according to Advanced Wound Management president Rohit Kashyap. Biomedical engineer Amit Gefen pointed to its ability to “dissipate shear forces” before they impact skin and tissue. Smith Nephew
There’s commercial heat here. Smith & Nephew pegs advanced wound management as a $12.5 billion market, where it holds the number two spot for revenue. Convatec gets a nod as a competitor in dressings, but investors still stack up Smith & Nephew’s orthopaedics business against heavyweights Stryker and Zimmer Biomet. Peer pressure isn’t theoretical, either: Convatec just bumped up its medium-term revenue growth target last month on the back of a fatter product pipeline and fresh wound-care launches.
Smith & Nephew posted 2025 revenue of $6.164 billion and a trading profit, as defined by the company, of $1.211 billion—a 15.5% increase—on March 2. For 2026, it’s guiding to around $1.3 billion in trading profit with sales expected to rise about 6% before currency swings. CEO Deepak Nath credited a robust fourth quarter for helping hit, or even exceed, the group’s 2025 benchmarks, and highlighted a “strong cadence” of new product launches coming in 2026. Smith Nephew
So far, investors aren’t convinced. Shares dropped over 5% on March 2, recovered 3.6% the next day as Barclays upped its price target, but by Thursday’s close, the stock remained down roughly 5% across five sessions.
But the launch hardly wipes out lingering risks. Smith & Nephew is staring at a $60 million tariff bill this year, even after already booking a $17 million hit in 2025. CEO Deepak Nath told Reuters that any Suez Canal closure would tack more days onto China-Europe shipping runs. The company has also sounded the alarm on weaker wound-bioactives demand ahead of coming reimbursement shifts. RBC’s Jack Reynolds-Clark flagged “significant risk of guidance downgrades” for the year. Reuters
Nath hasn’t budged, sticking to Smith & Nephew’s 2026 guidance as outlined back on March 2. Investors, though, seem to be holding out for evidence — they want to see new launches like ALLEVYN actually boost margins and grab market share, not just sit in the pipeline.
